Medical Oncology
Medical Director:
Prof. Dr. Dirk Jäger


Prof. Dr. Dirk Jäger is Managing Director of the National Center for Tumor Diseases (NCT) Heidelberg and Medical Director of the Medical Oncology Department at Heidelberg University Hospital (UKHD). The Department of Medical Oncology (Medical Clinic VI) is part of the Center for Internal Medicine at the UKHD and a core area of ​​the NCT Heidelberg.


NCT Tumorboard

Therapeutic Structures of Medical Oncology:

  • The Tumorambulanz (tumor outpatient clinic), where special consultation sessions are offered for most tumor patients, is the primary point of contact for oncological patients. A comprehensive consultancy service for patients and their families is also in place. Further information on appointments in the "For Patients" section.
  • In the outpatient clinic, systemic outpatient medical care is given.
  • The inpatient sector: Inpatient services are available for extensive diagnostic procedures and therapies. Some of these take place at the Department of Internal Medicine ("Medizinische Klinik"), the Department of Neurology ("Kopfklinik") and the Department of Surgery ("Chirurgische Klinik"). The NCT works in close clinical cooperation with the Salem Hospital, as well as the Vinzentius Hospital in Heidelberg, and the Kreiskrankenhaus Heppenheim. There are also cooperations with various oncological practice, who offer convenient patient care of the highest quality closer to home.

Interdisciplinary Tumorboard

Patients and doctors initially meet for the first time at the tumor board. Some of the consultations take place with a number of doctors from various disciplines, as part of entity-specific clinical cancer programs. This calls for close cooperation of all disciplines, but it also guarantees optimal care for the patient.


Standardized clinical pathways

The specialists in every cancer program define specific algorithms for each tumor entity (Standard Operating Procedures, SOPs), which are used for all patients diagnosed and treated at the NCT. In interdisciplinary tumor conferences, we work on individual therapy concepts for patients who can not be treated with an SOP, possibly due to emergence of a second tumor, having exhausted the current standard therapy, or in a relapse situation. The referring physician is always informed about any recommendations. Wherever appropriate, patients are encouraged to take part in clinical studies.

Scheme Patient pathway

If medicative therapy such as chemotherapy or immunotherapy is necessary, this can very often be administered in the outpatient clinic.

The application takes place in the day care units (Tagesklinik I and II). The day care units are open Monday to Friday between 8 am and 4 pm.